newsfilter
← Latest News
GlobeNewswire·

Tenax Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol Company Has Been Granted a Type C Meeting with the FDA CHAPEL HILL, N.C., Nov. 05, 2026